| Autor: |
Fredrik, Sundquist, Kleopatra, Georgantzi, Kirsten Brunsvig, Jarvis, Jesper, Brok, Minna, Koskenvuo, Jelena, Rascon, Max, van Noesel, Per, Grybäck, Joachim, Nilsson, Arthur, Braat, Mikael, Sundin, Sandra, Wessman, Nikolas, Herold, Lars, Hjorth, Per, Kogner, Dan, Granberg, Mark, Gaze, Jakob, Stenman |
| Rok vydání: |
2021 |
| Zdroj: |
Frontiers in pediatrics. 10 |
| ISSN: |
2296-2360 |
| Popis: |
Half the children with high-risk neuroblastoma die with widespread metastases. Molecular radiotherapy is an attractive systemic treatment for this relatively radiosensitive tumor.The LuDO-N trial is a phase II, open label, multi-center, single arm, two stage design clinical trial. Children aged 18 months to 18 years are eligible. The trial is conducted by the Nordic Society for Pediatric Hematology and Oncology (NOPHO) and it has been endorsed by SIOPEN (https://www.siopen.net). The Karolinska University Hospital, is the sponsor of the LuDO-N trial, which is conducted in collaboration with Advanced Accelerator Applications, a Novartis company. All Scandinavian countries, Lithuania and the Netherlands participate in the trial and the UK has voiced an interest in joining in 2022.The pediatric use of the Investigational Medicinal Product (IMP)In this paper we present the protocol of the LuDO-N Trial. The rationale and design of the trial are discussed in relation to other ongoing, or planned trials with similar objectives. Further, we discuss the rapid development of targeted radiopharmaceutical therapy and the future perspectives for developing novel therapies for high-risk neuroblastoma and other pediatric solid tumors. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
